A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

Summary

This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.

Timeline

Start

2025-02-24

Primary completion

2028-02-26

Completion

2028-08-30

Drugs

Indications